Literature DB >> 32804301

Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition.

Pranav Shah1, Kejal Chavda2, Bhavin Vyas2, Shailaja Patel2.   

Abstract

Linagliptin (LGP), a novel anti-diabetic drug, is a DPP-4 inhibitor used in the treatment of type II diabetes. One of the major disadvantages of LGP is its low oral bioavailability (29.5%) due to first-pass metabolism and P-gp efflux. In an attempt to increase the oral bioavailability, LGP solid lipid nanoparticles (LGP-SLNs) were developed with poloxamer 188 and Tween 80 as P-gp inhibitors. LGP-SLNs were formulated using palmitic acid, poloxamer 188 and Tween 80 as lipid, surfactant and co-surfactant, respectively, by hot homogenization ultrasonication method and optimized using 32 full factorial designs. Particle size, entrapment efficiency (%EE) and drug release at 24 h were evaluated as responses. An optimized batch of LGP-SLNs (L12) was evaluated for intestinal transport of LGP by conducting in situ single-pass intestinal perfusion (SPIP), everted gut sac and Caco-2 permeability study. The pharmacokinetic and pharmacodynamic evaluation of L12 was carried out in albino Wistar rats. The mean particle size, polydispersity index, zeta potential and %EE of L12 were found to be 225.96 ± 2.8 nm, 0.180 ± 0.034, - 5.4 ± 1.07 mV and 73.8 ± 1.73%, respectively. %CDR of 80.96 ± 3.13% was observed in 24 h. The permeability values of LGP-SLNs in the absorptive direction were 1.82-, 1.76- and 1.74-folds higher than LGP-solution (LGP-SOL) in SPIP, everted gut sac and Caco-2 permeability studies, respectively. LGP-SLNs exhibited relative bioavailability of 300% and better reduction in glucose levels in comparison with LGP-SOL in rats. The enhanced oral bioavailability exhibited by LGP-SLNs bioavailability may be due to P-gp efflux inhibition and lymphatic targeting. Improved bioabsorption can cause reduction in dose, dose-related side effects and frequency of administration. Thus, LGP-SLNs can be considered promising carriers for oral delivery but clinical studies are required to confirm the proof of concept.Graphical abstract.

Entities:  

Keywords:  Caco-2 permeability; In situ single-pass perfusion; Linagliptin; Oral bioavailability; P-glycoprotein inhibition; Pharmacodynamics; Pharmacokinetics

Mesh:

Substances:

Year:  2021        PMID: 32804301     DOI: 10.1007/s13346-020-00839-9

Source DB:  PubMed          Journal:  Drug Deliv Transl Res        ISSN: 2190-393X            Impact factor:   4.617


  58 in total

1.  Linagliptin monotherapy provides superior glycaemic control versus placebo or voglibose with comparable safety in Japanese patients with type 2 diabetes: a randomized, placebo and active comparator-controlled, double-blind study.

Authors:  R Kawamori; N Inagaki; E Araki; H Watada; N Hayashi; Y Horie; A Sarashina; Y Gong; M von Eynatten; H J Woerle; K A Dugi
Journal:  Diabetes Obes Metab       Date:  2012-01-17       Impact factor: 6.577

2.  AACE/ACE comprehensive diabetes management algorithm 2015.

Authors:  Alan J Garber; Martin J Abrahamson; Joshua I Barzilay; Lawrence Blonde; Zachary T Bloomgarden; Michael A Bush; Samuel Dagogo-Jack; Michael B Davidson; Daniel Einhorn; Jeffrey R Garber; W Timothy Garvey; George Grunberger; Yehuda Handelsman; Irl B Hirsch; Paul S Jellinger; Janet B McGill; Jeffrey I Mechanick; Paul D Rosenblit; Guillermo Umpierrez; Michael H Davidson
Journal:  Endocr Pract       Date:  2015-04-15       Impact factor: 3.443

3.  Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial.

Authors:  S Del Prato; A H Barnett; H Huisman; D Neubacher; H-J Woerle; K A Dugi
Journal:  Diabetes Obes Metab       Date:  2011-03       Impact factor: 6.577

4.  Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.

Authors:  A H Barnett; S Patel; R Harper; R Toorawa; S Thiemann; M von Eynatten; H-J Woerle
Journal:  Diabetes Obes Metab       Date:  2012-10-01       Impact factor: 6.577

5.  Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Authors:  R Gomis; R-M Espadero; R Jones; H J Woerle; K A Dugi
Journal:  Diabetes Obes Metab       Date:  2011-07       Impact factor: 6.577

Review 6.  DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials.

Authors:  A J Scheen
Journal:  Diabetes Metab       Date:  2011-12-22       Impact factor: 6.041

7.  Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Authors:  Thomas Haak; T Meinicke; R Jones; S Weber; M von Eynatten; H-J Woerle
Journal:  Diabetes Obes Metab       Date:  2012-03-21       Impact factor: 6.577

Review 8.  Gliptins: a new class of oral hypoglycaemic agent.

Authors:  H Chahal; T A Chowdhury
Journal:  QJM       Date:  2007-09-19

Review 9.  Inflammasomes and type 2 diabetes: An updated systematic review.

Authors:  Zahra Sepehri; Zohre Kiani; Mahdi Afshari; Farhad Kohan; Azadeh Dalvand; Saeid Ghavami
Journal:  Immunol Lett       Date:  2017-10-24       Impact factor: 3.685

10.  Vegetarian Diets in the Prevention and Management of Diabetes and Its Complications.

Authors:  Roman Pawlak
Journal:  Diabetes Spectr       Date:  2017-05
View more
  8 in total

1.  Amalgamation of Solid Dispersion and Melt Adsorption Technique: Improved In Vitro and In Vivo Performance of Ticagrelor Tablets.

Authors:  Mukesh Yadav; Jayant Sarolia; Bhavin Vyas; Manisha Lalan; Shubhada Mangrulkar; Pranav Shah
Journal:  AAPS PharmSciTech       Date:  2021-10-21       Impact factor: 3.246

2.  PEGylated SLN as a Promising Approach for Lymphatic Delivery of Gefitinib to Lung Cancer.

Authors:  Abdelrahman Y Sherif; Gamaleldin I Harisa; Fars K Alanazi; Fahd A Nasr; Ali S Alqahtani
Journal:  Int J Nanomedicine       Date:  2022-07-28

Review 3.  Nanocarrier Drug Delivery Systems: Characterization, Limitations, Future Perspectives and Implementation of Artificial Intelligence.

Authors:  Samar Zuhair Alshawwa; Abeer Ahmed Kassem; Ragwa Mohamed Farid; Shaimaa Khamis Mostafa; Gihan Salah Labib
Journal:  Pharmaceutics       Date:  2022-04-18       Impact factor: 6.525

4.  Synthesis, Characterization and In Vitro Evaluation of Chitosan Nanoparticles Physically Admixed with Lactose Microspheres for Pulmonary Delivery of Montelukast.

Authors:  Faqir Ullah; Kifayat Ullah Shah; Shefaat Ullah Shah; Asif Nawaz; Touseef Nawaz; Kamran Ahmad Khan; Raed F Alserihi; Hossam H Tayeb; Shams Tabrez; Mulham Alfatama
Journal:  Polymers (Basel)       Date:  2022-08-29       Impact factor: 4.967

Review 5.  Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.

Authors:  Priya Yadav; Suresh V Ambudkar; N Rajendra Prasad
Journal:  J Nanobiotechnology       Date:  2022-09-24       Impact factor: 9.429

6.  Investigation of the Potential of Nebivolol Hydrochloride-Loaded Chitosomal Systems for Tissue Regeneration: In Vitro Characterization and In Vivo Assessment.

Authors:  Noha Ibrahim Elsherif; Abdulaziz Mohsen Al-Mahallawi; Abdelfattah Ahmed Abdelkhalek; Rehab Nabil Shamma
Journal:  Pharmaceutics       Date:  2021-05-11       Impact factor: 6.321

Review 7.  Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations.

Authors:  Yana Zorkina; Olga Abramova; Valeriya Ushakova; Anna Morozova; Eugene Zubkov; Marat Valikhov; Pavel Melnikov; Alexander Majouga; Vladimir Chekhonin
Journal:  Molecules       Date:  2020-11-13       Impact factor: 4.411

Review 8.  Preparation of Solid Lipid Nanoparticles and Nanostructured Lipid Carriers for Drug Delivery and the Effects of Preparation Parameters of Solvent Injection Method.

Authors:  Van-An Duong; Thi-Thao-Linh Nguyen; Han-Joo Maeng
Journal:  Molecules       Date:  2020-10-18       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.